Product
SARS-CoV-2 Subunit Recombinant Protein
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
Immunogenicity & Safety of IndoVac® as a Homologous Booster Dose Against COVID-19 in Adults Aged 18 Years and Above in IndonesiaStatus: Not yet recruiting, Estimated PCD: 2023-11-01